
    
      This is an open-label (all people know the identity of the intervention), multi-center,
      prospective (look forward using observations collected following participant enrollment),
      non-comparative, non-randomized (the study medication is not assigned by chance), study.
      Safety and efficacy of paliperidone palmitate will be observed in Korean schizophrenic
      participants for 25 weeks. Approximately 3000 participants will be observed in this study and
      the study duration will be 25 weeks. Safety evaluations will include assessment of adverse
      events, concomitant medications, physical examination, and psychiatric history.
    
  